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Bevacizumab (Avastin®, Genethech, Inc.) is a humanized
monoclonal antibody that inhibits vascular endothelial
growth factor (VEGF). It was first approved by the US
food and drug administration for metastatic colorectal
cancer and subsequently for cervical/ovarian/fallopian
tube cancers, glioblastoma, non-small cell lung cancer,
and metastaic renal cell carcinoma [1]. Recently its off-
label use for age-related macular degeneration (AMD)
has received extensive attention. Single dose vial of in-
travitreal ranibizumab (IVR), another anti-VEGF anti-
body, has been licensed for treatment of wet AMD and
diabetic macular edema [1,2]. Due to lower cost and
reported equall efficacy and safety data in large clinicat
trials such as The Comparison of Age-related Macular
Degeneration Treatment Trial (CATT), The Inhibitors
of VEGF in Age-related Choroidal Neovascularization
(IVAN) and GEFAL studies, intravitreal bevacizumab
(IVB) has replaced the intravitreal administration of the
approved drug ranibizumab [2-7]. A recent review on
IVB administration for management of AMD and patho-
logical myopathy concluded that despite promising re-
sults, short-term patients’ follow-up in the available
studies, lack of well-designed extensive clinical trials,
and insufficient data on safety of IVB make its use
cautiously in these ocular diseases [8]. IVB administra-
tion has been widely used in other different proliferative
retinopathies including retinopathy of prematurity [9,10]
and diabetic retinopathy [9,11] as well. Angiogenesis
with key regulator VEGF is the main pathology in these
retinal and choroidal diseases [9]. A review on IVB
administration for treatment of different aforemen-
tioned retinal and choroidal diseases showed promising
reults [12].* Correspondence: mohammad@sina.tums.ac.ir
2Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran
University of Medical Sciences, Tehran 1417614411, Iran
Full list of author information is available at the end of the article
© 2015 Dashti-Khavidaki and Abdollahi; licens
the Creative Commons Attribution License (ht
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.IVB complications
Two categories of complications have been reported for
IVB: post-injection and drug class-related complications.
Post-injection complications that are not influenced by
the underlying ocular disease include infectious endoph-
thalmitis, sterile intraocular inflammation, rhegmatogen-
ous retinal detachment, increased intraocular pressure
and ocular hemorrhage. Drug-related dverse events
which are influenced by underlying ocular disease in-
clude development or progression of tractional retinal
detachment when IVB administration done before vi-
trectomy in patients with advanced proliferative diabetic
retinopathy, possible increase in the incidence of retinal
pigment epithelium tears in patients with AMD and
worsening retinal detachment in patients with severe
retinopathy of prematurity [9,12].
Preservative free vials of bevacizumab have not been
created for intravitreal administration.A recent system-
atic review with aim of evaluating the safety of IVB
monotherapy in adult ophthalmic conditions assessed 22
controlled trials and 67 observational studies that con-
tained at least 10 patients showed no difference in the
rate of endophthalmitis between the two groups of
patients receiving off-labeled IVB or licensed IVR [13].
There are several methods for preparing IVB including
multiple withdrawal from the same vial within the same
day or at different days under aseptic conditions by
ophthalmologist or preparing single use syringes of IVB
injection from bevacizumab vials by a compounding
pharmacy or a pharmaceutical company. Based on that
review,visual loss was the most commonly reported ocu-
lar event in patients who received IVB. Nine observa-
tional studies reported visual loss with an incidence rate
of 0 to 50%. The definition of visual loss was not clear in
most of these observational studies. It seems that in
these studies, visual loss occasionally was related to
other adverse events such as intraocular or anterior
chamber inflammation or retinal detachment. Therefore
the authors of that review doubted whether visual loss
happened due to IVB treatment or progression of theee BioMed Central. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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Dashti-Khavidaki and Abdollahi DARU Journal of Pharmaceutical Sciences  (2015) 23:27 Page 2 of 4patients’ diseases. Infectious endophthalmitis was reported
in 10 out of 13 observational studies with clinical inci-
dence rate of 0-1%. In three out of 13 studies in which
patients were treated with locally prepared IVB,the inci-
dence rates of infectious endophthalmitis were 0.02%,
0.2%, and 0.8%. A higher rate of endophthalmitis (0.9%)
was reported in the study in which IVB was prepared by
a compounding pharmaceutical company [13]. That re-
view concluded that IVB adverse effects are low and
comparable with other intravitreal treatments, sham in-
jection, and laser therapy [13].
A case-series from a private ophthalmology center from
Hong Kong showed that using the same bevacizumab
vial for maximum 10 consecutive injections with mul-
tiple aspiration of drug from the same vial under proper
sterile technique and discarding remaining drug at the
end of the day without overnight storage was safe. No
cases of endophthalmitis were reported with IVB from
that center [2]. A larger case series from Iran also
showed no cluster of endophthalmitis following mul-
tiple withdrawal from the same vial within the same day
with comparable risk of post-injection endophthalmitis
with other intravitreal treatment modalities [14]. Re-
cently, an Indian ophthalmology center reported a clus-
ter of clinically-proven endophthalmitis in 6 out of 8
patients who received IVB by multiple pricks of the
same bevacizumab vial (Avastin®, Genethech, Inc.) by
different tuberculin syringes under aseptic precautions
but not under the hood. The patients were treated with
intravitreal antibiotic administration, but only three
patients responded sufficiently. The culture from the
bevacizumb vial that had been used for those patients
and was kept refrigerated showed no microorganism
growth after four days [15].
Artunay et al. reported endophthalmitis incidence
rate of 0.066% after IVB, when multiple doses had been
withdrawn from a single vial in an out-patient setting
[16]. Other studies have also reported endophthalmitis
possibly due to contamination during the compounding
procedures of bevacizumab. Yamashiro et al. reported
culture-negative endophthalmitis in 14 out of 19 con-
secutive cases after IVB from a single batch of bevacizu-
mab [17]. Lee et al. reported two patients who received
IVB on the same day that developed endophthalmitis
with the same strains of Serratia marcescens suggesting
contamination during drug compounding. However,
they did not find any case of endophthalmitis in another
group of patients who received IVB aspirated from the
same vial that was reused for multiple consecutive injec-
tions just before each procedure and discarded on the
same day [18]. Similarly, the Pan-American Collaborative
Retina Study Group (PACORES) reported more frequent
endophthalmitis in eyes injected using previously com-
pounded aliquots than in eyes given injections from thesame multidose vial that was reused appropriately
(0.33 vs 0.04%) [19]. Unexpectedly,a higher frequency
of endophthalmitis was reported in patients utilizing
compounded aliquots by pharmaceutical company
compared to re-utilization of a single vial under aseptic
conditions [13]. Another cluster of infectious endoph-
thalmitis with Streptococcus mitis/oralis has been re-
ported in Maiami, Florida, United States in 12 patients.
IVB syringes for these patients had been prepared by a
compounding pharmacy in South Florida. The same
microorganism was found in cultures prepared from
unused syringes from this compounding pharmacy [20].Proposed strategies for IVB preparation
Although some studies have shown the stability and
sterility of compounded bevacizumab at 4°C up to
15 days or even 6 months, however, microbial contamin-
ation still remains a major concern since bevacizumab
vials are preservative free [21,22]. Multiple drawing from
the same vial increases the risk of contamination pos-
sibly due to wiping rubber septum by fingers or a dirty
gauze, rubber stopper leakage, poor aseptic technique
(e.g. entering the vial without alcohol swabbing), injec-
tion of air into the vial before solution removal, using a
contaminated needle or syringe for drug removal, and
inappropriate storage durations and temperatures
[23,24]. An extensive evaluation of IVB prepared by
eleven US academic compounding pharmacies under
good manufacturing practice facilities showed no micro-
bial or endotoxin contamination. However, there were
significant differences in bevacizumab concentrations
between prepared aliquots even those prepared in the
same compounding pharmacy. Bevacizumab concentra-
tions were lower than those expected in prepared
aliquots [25]. Some strategies have been reported to de-
crease the risk of IVB contamination. One proposed ap-
proach to minimize the risk of vial contamination
compared to the multiple prick method is to insert a 25
gauge needle into the rubber cap of the vial by single
prick and leaving the needle in place. The drug should
be drawn into different 1 mL syringes by every time
changing only the syringes not the needle. It is better to
use this vial for one day without overnight storage. Each
group of called patients should be small in number and
for unilateral, not bilateral, IVB [2,15]. According to the
United States Pharmacopeia (USP), the preparation of
IVB aliquots from bevacizumab vials may be categorized
to be in medium-risk level for sterile compounding. The
quality assurance procedures that recommended to be
considered include sterile preparation within a laminar-
airflow workbench, routine disinfection, air quality test-
ing to reach an International Organization for Standards
(ISO) class 5 environment and annual evaluations of
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sterile compounding [2,26].
Counterfeit Becacizumab
Medication counterfeiters are a major threat in drug
market all over the world. Expensive drugs such as
bevacizumab are at greater risk to be replaced with coun-
terfeiters. Therefore vigilance is needed by physicians,
drug distributors and governmental inspection agen-
cies. Detections of counterfeit Avastin in theUnited
States [27] and China [28] sparked worldwide con-
cerns. Cheng and Wei have reported an outbreak of
acute postoperative endophthalmitis in Shanghai,
China after IVB. They mainly incriminated off-label
IVB due to the potential risk of endophthalmitis. In
their report, 55 out of 116 patients who received IVB
from three bevacizumab vials showed endophthalmitis.
However, upon testing that bevacizumab batches,
Avastin manufacturer and an independent laboratory
both showed that there was no bevacizumab in the
vials. The cultures of ocular tissues of some of these
patients also were negative for any bacteria or fungi.
Visual acuities of all these patients were recovered by
topical or systemic corticosteroid therapy [28]. Cheng’s
and Wei’s concepts have been criticized by Sun et al.
because each expensive drug, including approved IVR
is at risk for counterfeiters [29]. Recently happening
some adverse effects following IVB treatment in sev-
eral patients in Iran prompted Ministry of Health and
Medical Education of Iran to warn pharmacies of
ophthalmology centers to prepare Bevacizumab vials
from approved pharmaceutical ditribution companies
to be safe from counterfeit bevacizumab (www.ifdona.ir.
Lettre number 655/153229 of Food and Drug Organization
of Ministry of Health and medical Education of Iran).Conclusion
There is growing body of articles on successful use of
IVB for the treatment of proliferative retinopathies.
Although the off-label use of a drug is not equivalent to
off-evidence use of that drug, however, until providing
single use, low content vials (1.25 or 2.5 mg) of
bevacizumab concerns for aseptic conditions and good
manufacturing process should be taken to account
when preparing aliquots from available preservative
free 100 mg/4 mL vials. It is more logical and cautious
to perform unilateral not bilateral IVB injection for
each patient at each procedur. Additionally, govern-
mental inspection agencies have to be more precise for
detection of Bevacizumab counterfeiters.Competing interests
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